JP2022534809A5 - - Google Patents
Info
- Publication number
- JP2022534809A5 JP2022534809A5 JP2021572556A JP2021572556A JP2022534809A5 JP 2022534809 A5 JP2022534809 A5 JP 2022534809A5 JP 2021572556 A JP2021572556 A JP 2021572556A JP 2021572556 A JP2021572556 A JP 2021572556A JP 2022534809 A5 JP2022534809 A5 JP 2022534809A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- improved
- grna
- protein
- casx
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025147107A JP2025183286A (ja) | 2019-06-07 | 2025-09-04 | 操作されたｃａｓｘシステム |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858750P | 2019-06-07 | 2019-06-07 | |
| US62/858,750 | 2019-06-07 | ||
| US201962944892P | 2019-12-06 | 2019-12-06 | |
| US62/944,892 | 2019-12-06 | ||
| US202063030838P | 2020-05-27 | 2020-05-27 | |
| US63/030,838 | 2020-05-27 | ||
| PCT/US2020/036505 WO2020247882A1 (en) | 2019-06-07 | 2020-06-05 | Engineered casx systems |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025147107A Division JP2025183286A (ja) | 2019-06-07 | 2025-09-04 | 操作されたｃａｓｘシステム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022534809A JP2022534809A (ja) | 2022-08-03 |
| JP2022534809A5 true JP2022534809A5 (enExample) | 2023-06-12 |
| JP7744011B2 JP7744011B2 (ja) | 2025-09-25 |
Family
ID=71899867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572556A Active JP7744011B2 (ja) | 2019-06-07 | 2020-06-05 | 操作されたｃａｓｘシステム |
| JP2025147107A Pending JP2025183286A (ja) | 2019-06-07 | 2025-09-04 | 操作されたｃａｓｘシステム |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025147107A Pending JP2025183286A (ja) | 2019-06-07 | 2025-09-04 | 操作されたｃａｓｘシステム |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US11560555B2 (enExample) |
| EP (1) | EP3980533A1 (enExample) |
| JP (2) | JP7744011B2 (enExample) |
| KR (1) | KR20220032050A (enExample) |
| CN (1) | CN114375334B (enExample) |
| AU (1) | AU2020289591A1 (enExample) |
| BR (1) | BR112021024288A2 (enExample) |
| CA (1) | CA3142883A1 (enExample) |
| CL (1) | CL2021003233A1 (enExample) |
| GB (1) | GB2600274B (enExample) |
| IL (1) | IL288738A (enExample) |
| MX (1) | MX2021015058A (enExample) |
| PE (1) | PE20220256A1 (enExample) |
| PH (1) | PH12021553076A1 (enExample) |
| SG (1) | SG11202113253SA (enExample) |
| TW (1) | TW202113074A (enExample) |
| WO (1) | WO2020247882A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12275964B2 (en) | 2018-08-22 | 2025-04-15 | The Regents Of The University Of California | Variant type V CRISPR/Cas effector polypeptides and methods of use thereof |
| EP3980533A1 (en) | 2019-06-07 | 2022-04-13 | Scribe Therapeutics Inc. | Engineered casx systems |
| WO2021050601A1 (en) | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| WO2021050593A1 (en) | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of sod1 |
| WO2021113763A1 (en) | 2019-12-06 | 2021-06-10 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of rhodopsin |
| IL294620A (en) * | 2020-01-10 | 2022-09-01 | Scribe Therapeutics Inc | Compositions and methods for the targeting of pcsk9 |
| AU2021237633A1 (en) | 2020-03-18 | 2022-10-06 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of C9orf72 |
| GB202010075D0 (en) * | 2020-07-01 | 2020-08-12 | Imp College Innovations Ltd | Therapeutic nucleic acids, peptides and uses |
| WO2022119957A1 (en) * | 2020-12-02 | 2022-06-09 | The Regents Of The University Of California | Crispr-cas effector polypeptides and methods of use thereof |
| KR20230128289A (ko) | 2020-12-03 | 2023-09-04 | 스크라이브 테라퓨틱스 인크. | 조작된 클래스 2 유형 v crispr 시스템 |
| US20240100185A1 (en) | 2020-12-03 | 2024-03-28 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of ptbp1 |
| WO2022125843A1 (en) | 2020-12-09 | 2022-06-16 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| TW202302844A (zh) * | 2021-03-09 | 2023-01-16 | 美商阿伯生物技術公司 | 包含變異多肽之組合物及其用途 |
| EP4347818A2 (en) | 2021-06-01 | 2024-04-10 | Arbor Biotechnologies, Inc. | Gene editing systems comprising a crispr nuclease and uses thereof |
| WO2022261149A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| GB2625500B (en) | 2021-09-21 | 2026-04-01 | Scribe Therapeutics Inc | Engineered CasX repressor systems |
| EP4405490A2 (en) | 2021-09-23 | 2024-07-31 | Scribe Therapeutics Inc. | Self-inactivating vectors for gene editing |
| CN116497002A (zh) * | 2022-01-19 | 2023-07-28 | 中国科学院动物研究所 | 工程化的CasX核酸酶、效应蛋白及其用途 |
| WO2023235818A2 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| WO2023235888A2 (en) | 2022-06-03 | 2023-12-07 | Scribe Therapeutics Inc. | COMPOSITIONS AND METHODS FOR CpG DEPLETION |
| TW202413643A (zh) | 2022-06-07 | 2024-04-01 | 美商斯奎柏治療公司 | 用於靶向pcsk9的組合物及方法 |
| WO2023240027A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Particle delivery systems |
| GB2634837A (en) | 2022-06-07 | 2025-04-23 | Scribe Therapeutics Inc | Compositions and methods for the targeting of PCSK9 |
| US20250361525A1 (en) | 2022-06-08 | 2025-11-27 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| WO2023240157A2 (en) | 2022-06-08 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of dmd |
| WO2024081711A2 (en) * | 2022-10-11 | 2024-04-18 | The Broad Institute, Inc. | Reprogramable tnpb polypeptides and use thereof |
| KR20250151430A (ko) | 2023-02-15 | 2025-10-21 | 아버 바이오테크놀로지스, 인크. | 스타스민 2(stmn2) 전사체에서 비정상적인 스플라이싱을 억제하는 유전자 편집 방법 |
| AU2024236558A1 (en) | 2023-03-15 | 2025-10-09 | Renagade Therapeutics Management Inc. | Delivery of gene editing systems and methods of use thereof |
| WO2024206565A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Repressor fusion protein systems |
| PE20252746A1 (es) | 2023-03-29 | 2025-12-05 | Scribe Therapeutics Inc | Composiciones y metodos para el direccionamiento a pcsk9 |
| WO2024206620A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Messenger rna encoding casx |
| WO2024206676A1 (en) | 2023-03-29 | 2024-10-03 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of lpa |
| CN116926043B (zh) * | 2023-04-28 | 2024-09-06 | 新乡医学院第三附属医院 | 一种dCasX蛋白核酸酶、重组载体及其应用 |
| EP4705445A2 (en) * | 2023-05-02 | 2026-03-11 | Inari Agriculture Technology, Inc. | Ribozyme sequences for processing rna |
| AU2024270764A1 (en) | 2023-05-15 | 2025-12-04 | Nchroma Bio, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| JPWO2024257843A1 (enExample) * | 2023-06-16 | 2024-12-19 | ||
| AU2024335327A1 (en) | 2023-09-01 | 2026-03-26 | Renagade Therapeutics Management Inc. | Gene editing systems, compositions, and methods for treatment of vexas syndrome |
| WO2025072293A1 (en) | 2023-09-27 | 2025-04-03 | Scribe Therapeutics Inc. | Optimized mrnas encoding casx proteins |
| CN117296799B (zh) * | 2023-11-28 | 2024-02-02 | 四川省医学科学院·四川省人民医院 | 一种视网膜色素变性疾病模型的构建方法及其应用 |
| WO2025171210A1 (en) | 2024-02-09 | 2025-08-14 | Arbor Biotechnologies, Inc. | Compositions and methods for gene editing via homology-mediated end joining |
| WO2025174765A1 (en) | 2024-02-12 | 2025-08-21 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
| WO2025240940A1 (en) | 2024-05-17 | 2025-11-20 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of apolipoprotein c3 |
| WO2026015832A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Reverse transcriptases and gene editing systems comprising such |
| WO2026015829A2 (en) | 2024-07-12 | 2026-01-15 | Arbor Biotechnologies, Inc. | Small reverse transcriptases and gene editing systems comprising such |
| CN120424908B (zh) * | 2025-07-10 | 2025-09-12 | 南京农业大学 | 一种基于LAMP与CRISPR/Cas的检测方法和应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| EP1179340A3 (en) | 1994-09-30 | 2003-05-07 | INEX Pharmaceutical Corp. | Compositions for the introduction of polyanionic materials into cells |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| JP4764426B2 (ja) | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
| WO2007086881A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| CA2742969A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| WO2010075303A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| WO2012068627A1 (en) | 2010-11-24 | 2012-05-31 | The University Of Western Australia | Peptides for the specific binding of rna targets |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| CA2969619A1 (en) | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| JP2018509387A (ja) | 2015-01-21 | 2018-04-05 | フェーズアールエックス インコーポレイテッド | 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム |
| AU2016279077A1 (en) | 2015-06-18 | 2019-03-28 | Omar O. Abudayyeh | Novel CRISPR enzymes and systems |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| CN116814590A (zh) | 2015-10-22 | 2023-09-29 | 布罗德研究所有限公司 | Vi-b型crispr酶和系统 |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| WO2017083722A1 (en) | 2015-11-11 | 2017-05-18 | Greenberg Kenneth P | Crispr compositions and methods of using the same for gene therapy |
| EP3390624A4 (en) | 2015-12-18 | 2019-07-10 | The Regents of The University of California | Modified site-directed modifying polypeptides and methods of use thereof |
| US9896696B2 (en) | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| EP3468612A1 (en) | 2016-06-09 | 2019-04-17 | CureVac AG | Hybrid carriers for nucleic acid cargo |
| WO2017212007A1 (en) | 2016-06-09 | 2017-12-14 | Curevac Ag | Cationic carriers for nucleic acid delivery |
| AU2017280353B2 (en) | 2016-06-24 | 2021-11-11 | Inscripta, Inc. | Methods for generating barcoded combinatorial libraries |
| EP3500967A1 (en) | 2016-08-17 | 2019-06-26 | The Broad Institute, Inc. | Methods for identifying class 2 crispr-cas systems |
| MX2019003674A (es) * | 2016-09-30 | 2021-01-08 | Univ California | Enzimas modificadoras de ácido nucleico guiadas por arn y métodos de uso de estas. |
| US9982267B2 (en) | 2016-10-12 | 2018-05-29 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| ES2928176T3 (es) | 2017-01-10 | 2022-11-16 | Christiana Care Gene Editing Inst Llc | Métodos para mutagénesis dirigida al sitio in vitro mediante el uso de tecnologías de edición de genes |
| US20190367924A1 (en) * | 2017-02-17 | 2019-12-05 | Temple University - Of The Commonwealth System Of Higher Education | Gene editing therapy for hiv infection via dual targeting of hiv genome and ccr5 |
| SG11201906297QA (en) | 2017-03-24 | 2019-10-30 | Curevac Ag | Nucleic acids encoding crispr-associated proteins and uses thereof |
| WO2018195555A1 (en) | 2017-04-21 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors |
| US11578334B2 (en) | 2017-10-25 | 2023-02-14 | Monsanto Technology Llc | Targeted endonuclease activity of the RNA-guided endonuclease CasX in eukaryotes |
| US10253365B1 (en) | 2017-11-22 | 2019-04-09 | The Regents Of The University Of California | Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs |
| WO2019168950A1 (en) | 2018-02-27 | 2019-09-06 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating angelman syndrome |
| US20200224160A1 (en) | 2018-02-27 | 2020-07-16 | Sorrento Therapeutics, Inc. | Process for dna integration using rna-guided endonucleases |
| WO2019213273A1 (en) | 2018-05-01 | 2019-11-07 | The Children's Medical Center Corporation | Enhanced bcl11a rnp / crispr delivery & editing using a 3xnls-cas9 |
| EP3818167A4 (en) | 2018-07-05 | 2022-04-13 | The Regents of The University of California | COMPOSITIONS AND METHODS FOR DELIVERING RNA TO A CELL |
| US20210284981A1 (en) | 2018-07-24 | 2021-09-16 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| US12275964B2 (en) | 2018-08-22 | 2025-04-15 | The Regents Of The University Of California | Variant type V CRISPR/Cas effector polypeptides and methods of use thereof |
| WO2020247883A2 (en) | 2019-06-07 | 2020-12-10 | Scribe Therapeutics Inc. | Deep mutational evolution of biomolecules |
| EP3980533A1 (en) | 2019-06-07 | 2022-04-13 | Scribe Therapeutics Inc. | Engineered casx systems |
| US12454685B2 (en) | 2019-07-08 | 2025-10-28 | The Regents Of The University Of California | Variant type V CRISPR/Cas effector polypeptides and methods of use thereof |
| CN114340656B (zh) | 2019-08-02 | 2024-07-30 | 孟山都技术公司 | 使用huh内切核酸酶促进靶向基因组修饰的方法和组合物 |
| WO2021050601A1 (en) | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
| WO2021050593A1 (en) | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of sod1 |
| WO2021084533A1 (en) | 2019-10-28 | 2021-05-06 | Targetgene Biotechnologies Ltd | Pam-reduced and pam-abolished cas derivatives compositions and uses thereof in genetic modulation |
| WO2021113763A1 (en) | 2019-12-06 | 2021-06-10 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of rhodopsin |
| EP4069716A1 (en) | 2019-12-06 | 2022-10-12 | Scribe Therapeutics Inc. | Particle delivery systems |
| EP4069846A1 (en) | 2019-12-07 | 2022-10-12 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of htt |
| IL294620A (en) | 2020-01-10 | 2022-09-01 | Scribe Therapeutics Inc | Compositions and methods for the targeting of pcsk9 |
| AU2021237633A1 (en) | 2020-03-18 | 2022-10-06 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of C9orf72 |
| KR20230128289A (ko) | 2020-12-03 | 2023-09-04 | 스크라이브 테라퓨틱스 인크. | 조작된 클래스 2 유형 v crispr 시스템 |
| WO2022261149A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| GB2625500B (en) | 2021-09-21 | 2026-04-01 | Scribe Therapeutics Inc | Engineered CasX repressor systems |
| EP4405490A2 (en) | 2021-09-23 | 2024-07-31 | Scribe Therapeutics Inc. | Self-inactivating vectors for gene editing |
| WO2023235818A2 (en) | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
-
2020
- 2020-06-05 EP EP20750444.0A patent/EP3980533A1/en active Pending
- 2020-06-05 SG SG11202113253SA patent/SG11202113253SA/en unknown
- 2020-06-05 AU AU2020289591A patent/AU2020289591A1/en active Pending
- 2020-06-05 WO PCT/US2020/036505 patent/WO2020247882A1/en not_active Ceased
- 2020-06-05 KR KR1020227000734A patent/KR20220032050A/ko active Pending
- 2020-06-05 TW TW109119111A patent/TW202113074A/zh unknown
- 2020-06-05 GB GB2200132.5A patent/GB2600274B/en active Active
- 2020-06-05 MX MX2021015058A patent/MX2021015058A/es unknown
- 2020-06-05 CA CA3142883A patent/CA3142883A1/en active Pending
- 2020-06-05 JP JP2021572556A patent/JP7744011B2/ja active Active
- 2020-06-05 BR BR112021024288A patent/BR112021024288A2/pt unknown
- 2020-06-05 PH PH1/2021/553076A patent/PH12021553076A1/en unknown
- 2020-06-05 PE PE2021002050A patent/PE20220256A1/es unknown
- 2020-06-05 CN CN202080056141.9A patent/CN114375334B/zh active Active
-
2021
- 2021-11-23 US US17/533,997 patent/US11560555B2/en active Active
- 2021-12-03 US US17/542,219 patent/US20220220508A1/en active Pending
- 2021-12-06 IL IL288738A patent/IL288738A/en unknown
- 2021-12-06 CL CL2021003233A patent/CL2021003233A1/es unknown
-
2022
- 2022-11-22 US US18/058,251 patent/US12084692B2/en active Active
-
2024
- 2024-07-19 US US18/778,393 patent/US20250043262A1/en active Pending
- 2024-10-08 US US18/909,093 patent/US20250136962A1/en active Pending
-
2025
- 2025-09-04 JP JP2025147107A patent/JP2025183286A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022534809A5 (enExample) | ||
| JP7374119B2 (ja) | 減少した肝臓向性を有するＡＡＶ９とＡＡＶｒｈ７４とのハイブリッド組換えアデノ随伴ウイルス血清型 | |
| US12472239B2 (en) | Guide RNA for repairing a mutant human titin gene using CRISPR technology | |
| JP7651190B2 (ja) | 遺伝子操作ｒｎａを用いた内因性ａｄａｒによる標的化ｒｎａ編集 | |
| GB2600274A (en) | Engineered CasX systems | |
| JP2023552374A5 (enExample) | ||
| JP7381494B2 (ja) | 転写調節要素及びその使用 | |
| JP7832262B2 (ja) | 肝特異的ウイルスプロモーター及びその使用方法 | |
| EP3931331A1 (en) | Aav vector-mediated deletion of large mutational hotspot for treatment of duchenne muscular dystrophy | |
| JP2023518541A5 (enExample) | ||
| JP2022505381A5 (enExample) | ||
| JP2017529854A (ja) | 高効率ゲノム編集のためのアデノ随伴ウイルスベクターバリアント及びその方法 | |
| JP2023537625A5 (enExample) | ||
| JP2022541070A (ja) | 調節可能な発現系 | |
| JP7481755B2 (ja) | 組換えパルボウイルスベクターならびにその作製および使用方法 | |
| JP2023552379A5 (enExample) | ||
| CN114072497B (zh) | 用于调控酶表达和使酶表达自失活的组合物以及用于调节酶的脱靶活性的方法 | |
| JP2022553573A5 (enExample) | ||
| CN119403823A (zh) | 具有增强的肌肉转导效率的肽修饰的aav衣壳 | |
| WO2025061173A1 (zh) | 一种融合蛋白及其应用 | |
| EP4441232A2 (en) | Functional aav capsids for intravitreal administration | |
| CN120818522B (zh) | 一种基于itr-增强子驱动核酸表达的调控元件组合及其应用 | |
| TWI838812B (zh) | 用於治療法布瑞氏症之組合物及方法 | |
| Fakhiri et al. | 254. New Chimeric Gene Therapy Vectors Based on Four Different Mammalian Bocaviruses | |
| WO2025006957A2 (en) | Non-neutralizing aav constructs and methods of generating and using same |